Silexion reports preclinical data showing SIL204 reaches metastatic sites in pancreatic cancer model

Silexion Therapeutics Corp

Subcutaneous SIL204 (5 mg/mouse) distributed to liver, peritoneum, lung in Panc-1 KRAS G12D metastatic model.
Tumor burden reduced significantly (p<0.01) in peritoneum, lung, intestine; liver showed measurable reduction.
Data supports dual-route strategy: intratumoral for primary tumor, systemic for metastases.
Phase 2/3 trial on track for H1 2026; regulatory submissions planned Q4 2025 and Q1 2026.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.